What can I claim secondary to human immunodeficiency virus infection?
7 conditions in the Repatriation Medical Authority's Statements of Principles list human immunodeficiency virus infection as a factor. If DVA has accepted your human immunodeficiency virus infection, each of these has a documented pathway to a further claim.
At a glance
- Accepted conditionHuman immunodeficiency virus infection
- Conditions it may open7
- SourceRMA SoPs
- Chart Review$600 + GST
How a secondary claim works
Some Statement of Principles factors are not about service at all — they name another condition. Where DVA has already accepted your human immunodeficiency virus infection, and another condition's SoP lists human immunodeficiency virus infection as a factor, that part of the next claim is already established on your file. How a secondary claim works, in full →
Conditions that list human immunodeficiency virus infection as a factor
Quoted from the instrument. A pathway existing is not the same as a claim succeeding — each factor carries thresholds your record has to satisfy.
Adhesive capsulitis of the shoulder
RH No. 72 of 2020 · BoP No. 73 of 2020
Reasonable Hypothesis — factor (10): “taking highly active antiretroviral therapy for human immunodeficiency virus infection at the time of the clinical onset of adhesive capsulitis of the shoulder” [clinical onset] — factor (21): “taking highly active antiretroviral therapy for human immunodeficiency virus infection at the time of the clinical worsening of adhesive capsulitis of the shoulder” [worsening]
Balance of Probabilities — factor (9): “taking highly active antiretroviral therapy for human immunodeficiency virus infection at the time of the clinical onset of adhesive capsulitis of the shoulder” [clinical onset] — factor (18): “taking highly active antiretroviral therapy for human immunodeficiency virus infection at the time of the clinical worsening of adhesive capsulitis of the shoulder” [worsening]
Adrenal insufficiency
RH No. 71 of 2018 · BoP No. 72 of 2018
Reasonable Hypothesis — factor (9): “being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for a continuous period of at least four weeks before the clinical onset of adrenal insufficiency; and (b) where such treatment has ceased, the last dose was received within the three months before the clinical onset of adrenal insufficiency” [clinical onset] — factor (21): “being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for a continuous period of at least four weeks before the clinical worsening of adrenal insufficiency; and (b) where such treatment has ceased, the last dose was received within the three months before the clinical worsening of adrenal insufficiency” [worsening]
Balance of Probabilities — factor (9): “being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for a continuous period of at least four weeks before the clinical onset of adrenal insufficiency; and (b) where such treatment has ceased, the last dose was received within the three months before the clinical onset of adrenal insufficiency” [clinical onset] — factor (21): “being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for a continuous period of at least four weeks before the clinical worsening of adrenal insufficiency; and (b) where such treatment has ceased, the last dose was received within the three months before the clinical worsening of adrenal insufficiency” [worsening]
Cushing syndrome
RH No. 43 of 2018 · BoP No. 44 of 2018
Reasonable Hypothesis — factor (3): “being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for at least four weeks before the clinical onset of Cushing syndrome; and (b) where treatment has ceased, the clinical onset of Cushing syndrome has occurred within 30 days of cessation” [clinical onset]
Balance of Probabilities — factor (3): “being treated with medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for at least four weeks before the clinical onset of Cushing syndrome; and (b) where treatment has ceased, the clinical onset of Cushing syndrome has occurred within 30 days of cessation” [clinical onset]
Hepatitis e infection
RH No. 39 of 2024 · BoP No. 40 of 2024
Reasonable Hypothesis — factor (5): “having human immunodeficiency virus infection at the time of clinical worsening” [worsening]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Hypertension
RH No. 21 of 2022 · BoP No. 22 of 2022
Reasonable Hypothesis — factor (17): “taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for at least 28 days before the clinical onset of hypertension; and (b) if treatment has ceased before the clinical onset of hypertension, then that onset occurred within 30 days of cessation” [clinical onset] — factor (42): “taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for at least 28 days before the clinical worsening of hypertension; and (b) if treatment has ceased before the clinical worsening of hypertension, then that worsening occurred within 30 days of cessation” [worsening]
Balance of Probabilities — factor (16): “taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for at least 28 days before the clinical onset of hypertension; and (b) if treatment has ceased before the clinical onset of hypertension, then that onset occurred within 30 days of cessation” [clinical onset] — factor (34): “taking medroxyprogesterone acetate or megestrol acetate for a malignant disease or human immunodeficiency virus infection: (a) for at least 28 days before the clinical worsening of hypertension; and (b) if treatment has ceased before the clinical worsening of hypertension, then that worsening occurred within 30 days of cessation” [worsening]
Osteoporosis
RH No. 66 of 2024
Reasonable Hypothesis — factor (3): “having human immunodeficiency virus infection for at least the 1 year before clinical onset or clinical worsening” [onset and worsening]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Sarcoidosis
RH No. 60 of 2025 · BoP No. 61 of 2025
Reasonable Hypothesis — factor (2): “being treated for human immunodeficiency virus infection with antiretroviral drugs within the 2 years before clinical onset or clinical worsening” [onset and worsening]
This factor appears in the Reasonable Hypothesis instrument only, which applies to operational service.
Other accepted conditions that also open adhesive capsulitis of the shoulder
If any of these is also on your file, it reaches some of the same conditions human immunodeficiency virus infection does.
What DVA means by human immunodeficiency virus infection
A claim is tested against the definition first. If the diagnosis on your file does not meet this wording, the factors below never get reached — so it is worth checking that what your doctor wrote matches what the instrument requires.
Human immunodeficiency virus infection, for the purposes of the Statement of Principles, for the purposes of this Statement of Principles, human immunodeficiency virus infection means an infection that is caused by one of the human retroviruses, human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2). (3) While human immunodeficiency virus infection attracts ICD-10-AM code B20, B21, B22, B23, B24 or Z21, in applying this Statement of Principles the meaning of human immunodeficiency virus infection is that given in subsection (2). (4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.
Aggravation-only factors. In this instrument, subsections 9(4) apply only to material contribution to, or aggravation of, human immunodeficiency virus infection where it was already present before or during service. If service caused human immunodeficiency virus infection outright, those factors are not available to you.
RH No. 5 of 2019 · BoP No. 6 of 2019 · 5 factors
Every factor in the human immunodeficiency virus infection SoP →
What could support a claim for human immunodeficiency virus infection?
The Statement of Principles for human immunodeficiency virus infection names 2 other conditions among its own factors. If any of these is already accepted on your file, it may be the factor that carries a human immunodeficiency virus infection claim — quoted here from the instrument.
Herpes simplex
Reasonable Hypothesis — factor (2): “having: (a) a genital ulcerative disease; or (b) a non-ulcerative anogenital sexually transmitted infection with clinical symptoms or signs, excluding genital warts; or (c) herpes simplex virus type 2 anogenital infection; within the 30 days before the clinical onset of human immunodeficiency virus infection” [clinical onset]
Balance of Probabilities — factor (2): “having: (a) a genital ulcerative disease; or (b) a non-ulcerative anogenital sexually transmitted infection with clinical symptoms or signs, excluding genital warts; or (c) herpes simplex virus type 2 anogenital infection; within the 30 days before the clinical onset of human immunodeficiency virus infection” [clinical onset]
Tuberculosis
Balance of Probabilities — factor (4): “having tuberculosis at the time of the clinical worsening of human immunodeficiency virus infection” [worsening]
Reviewed by Dr Thomas Perkins
Founding doctor, Veterans Health Centre · former RAAF aviation medical officer · 13 years working exclusively with ADF members and veterans. Full profile →
Human immunodeficiency virus infection accepted?
Contact us for more information.